This study is looking at whether treating depression improves outcomes for people with chronic kidney disease (CKD). Researchers know that depression is common in CKD patients and can lead to worse health, hospital stays, and even death. This trial will test two approaches: the antidepressant medication bupropion, and behavioral activation therapy (a type of talk therapy delivered by video). Some participants will receive one treatment, and others will receive both. The main goal is to see if these treatments improve depression symptoms. You may be able to join if you are an adult with CKD stages 3b, 4, or 5 and also have major depressive disorder. The study aims to enroll 201 participants, but the current recruitment status is unclear.

Study design

This interventional study will randomly assign 201 participants into one of three groups to compare different treatment strategies. It involves both single-blind (you won't know if you're getting bupropion or placebo) and double-blind (neither you nor your doctor will know) elements.

What's involved

Participants will receive treatment for 16 weeks. Depression symptoms will be assessed at the start, and at weeks 4, 6, 8, 12, and 16.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 16 weeks, with assessments at baseline and weeks 4, 6, 8, 12, and 16.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.